Infections

Mouth and Tooth Diseases

Nervous System Diseases

All Conditions

Symptoms and General Pathology

Digestive System Diseases

Ear, Nose, and Throat Diseases

Musculoskeletal Diseases

Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

Behaviors and Mental Disorders

Rare Diseases

Bell Palsy

Facial Paralysis

Facies

Paralysis

Xerostomia

Deglutition Disorders

Polymyositis

Speech Disorders

Otorhinolaryngologic Diseases

Pharyngeal Neoplasms

Laryngeal Diseases

Dysarthria

Otorhinolaryngologic Neoplasms

Myositis

Muscular Diseases

Neuromuscular Diseases

Language Disorders

Communication Disorders

Neurobehavioral Manifestations

Neurologic Manifestations

Head and Neck Neoplasms

Pharyngeal Diseases

Stomatognathic Diseases

Bell's Palsy

Idiopathic Inflammatory Myopathy

This study will assess the use of ultrasound-a test that uses sound waves to produce images-as a diagnostic tool for evaluating speech and swallowing.

The following categories of individuals may be eligible for this study: 1) healthy volunteers between 20 and 85 years old with normal speech and hearing, 2) patients 6 to 85 years old with developmental neurological deficits in speech or swallowing, and 3) patients with tumors of the oral cavity, pharynx or larynx being treated at the Greater Baltimore Medical Center.

Participants will undergo a 30-minute speech and oral motion evaluation, in which they imitate sounds, words and oral movements while a speech pathologist evaluates their lip, tongue and palate movements. They may also be asked to drink a small amount of water for examination of swallowing function.

For the ultrasound examination, a 3/4-inch transducer (device for transmitting and receiving sound waves) is placed under the participant's chin. While the transducer is in place, the subject 1) repeats sounds and a series of syllables in several sequences, 2) swallows three times with and without a small amount of water, and 3) swallows 3 teaspoons of non-fat pudding. The ultrasound images are recorded on tape for later analysis.

Studies conducted using ultrasound imaging at the NIH, Departments of Rehabilitation Medicine and Diagnostic Radiology, have demonstrated that ultrasound imaging can be used reliably to study speech and swallowing impairments in a variety of conditions and diseases. Since ultrasound is non-invasive with no reported bioeffects, it can be used repeatedly to follow the progression of a disease. Ultrasound imaging of the oral cavity during speech and swallowing allows easy visualization of the tongue/hyoid bone motion and transport of the bolus during swallowing and tongue surface configuration during speech. Images can be obtained in several planes for viewing muscular coordination and timing and specific measures can be obtained from digitized video images. Thus it has widespread clinical research implications for patients with disorders affecting the oral peripheral muscles, salivary gland flow and the central nervous system control of speech and swallowing. While ultrasound technology has been used extensively in Europe to evaluate tumors of the head and neck, its use in this country has been marginal. We plan to compare ultrasound evaluation of tumor staging, tumor volume, and tumor recurrence in patients with tumors of the larynx, oral cavity and hypopharynx. Currently, this is accomplished by CT or MRI scanning procedures. We plan to compare CT/MRI results with ultrasound to determine if this non-invasive technique can be utilized reliably for diagnosis and tracking of oropharyngeal tumors.

Ultrasound Evaluation of Tongue Movements in Speech and Swallowing

Exploration of the Diagnostic Capabilities of Ultrasound of the Oropharynx and Larynx

National Institutes of Health Clinical Center (CC)

Carcinoma

Carcinoma, Squamous Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Oral Squamous Cell Carcinoma

Tongue Cancer

All Drugs and Chemicals

Vaccines

Immunomodulating Agents

Allovectin-7®

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.

Treatment - If you take part in this trial you will be treated for about four weeks. You will receive an injection of Allovectin-7® by needle, directly into your tumor. This will be repeated 14 days later. The injections may be given in a doctor's office. A week later, you will undergo surgery to remove the tumor. Your tumor will be measured before Allovectin-7® treatment and before surgery to see if Allovectin-7® was effective in shrinking it. This will be done by general physical exams and scans (such as X-ray scans). There will also be tests on the removed tumor to see if Allovectin-7® helped to boost the immune system to attack the cancer.

Phase II Trial of Allovectin-7® for Head and Neck Cancer

Phase II Study of the Safety and Efficacy of Allovectin-7® Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Vical

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Ultrasound Evaluation of Tongue Movements in Speech and Swallowing	NCT00001167	Otorhinolaryngo... Otorhinolaryngo... Pharyngeal Neop... Polymyositis Speech Disorder		-	National Institutes of Health Clinical Center (CC)
Phase II Trial of Allovectin-7® for Head and Neck Cancer	NCT00050388	Head and Neck C... Squamous Cell C... Head and Neck N... Carcinoma of th...	Allovectin-7®	18 Years -	Vical

Spots Global Cancer Trial Database for otorhinolaryngologic neoplasm